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ABSTRACT 1 
Purpose 2 
CHEK2*1100delC is a founder variant in European populations conferring a 2-3 fold increased risk of 3 
breast cancer (BC). Epidemiologic and family studies have suggested that the risk associated with 4 
CHEK2*1100delC is modified by other genetic factors in a multiplicative fashion. We have 5 
investigated this empirically using data from the Breast Cancer Association Consortium (BCAC).  6 
Methods 7 
With genotype data of 39,139 (624 1100delC carriers) BC patients and 40,063 (224) healthy controls 8 
from 32 BCAC studies, we analyzed the combined risk effects of CHEK2*1100delC and 77 common 9 
variants in terms of a polygenic risk score (PRS) and pairwise interaction.  10 
Results 11 
The PRS conferred an odds ratio (OR) of 1.59 [95% CI 1.21-2.09] per standard deviation for BC for 12 
CHEK2*1100delC carriers and 1.58 [1.55-1.62] for non-carriers. No evidence for deviation from the 13 
multiplicative model was found. The OR for the highest quintile of the PRS was 2.03 [0.86-4.78] for 14 
CHEK2*1100delC carriers placing them to the high risk category according to UK NICE guidelines. OR 15 
for the lowest quintile was 0.52 [0.16-1.74], indicating life-time risk close to population average.  16 
Conclusion 17 
Our results confirm the multiplicative nature of risk effects conferred by CHEK2*1100delC and the 18 
common susceptibility variants. Furthermore, the PRS could identify the carriers at a high life-time 19 
risk for clinical actions. 20 
Keywords: Breast cancer; CHEK2*1100delC; Polygenic risk score (PRS); common variants; Breast 21 
Cancer Association Consortium (BCAC) 22 
23 
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INTRODUCTION 1 
The protein truncating mutation CHEK2*1100delC (checkpoint kinase 2) is a moderate penetrance 2 
breast cancer risk variant with relative risk estimate of 2-3 fold.1, 2 However, several studies have 3 
shown that the cumulative life-time risk of breast cancer in CHEK2*1100delC carriers is markedly 4 
higher in women with a family history than without,3-5 and that CHEK2*1100delC carriers have a 5 
higher probability of developing bilateral breast cancer.6 These observations are quantitatively 6 
consistent with a simple polygenic model suggesting that CHEK2*1100delC combines multiplicatively 7 
with other genetic loci. However, this has not yet been established empirically.   8 
Genome wide association studies have identified common genetic variants that are associated with 9 
increased risk of breast cancer. A polygenic risk score (PRS), based on 77 low penetrance variants has 10 
been estimated to explain approximately 12-14% of the excess familial risk and shown to identify 11 
individuals at high risk at the population level.7, 8 Some of these variants predominantly predispose 12 
to either estrogen receptor positive (ER+) or estrogen receptor negative (ER-) disease, which 13 
represent the two main etiological subclasses of breast cancer.9 CHEK2*1100delC carriers are more 14 
strongly predisposed to ER+ disease: about 90% of carrier tumors are ER+ in comparison to 77-78% 15 
of non-carrier tumours.10  16 
Here, we investigate the synergistic risk effects attributable to CHEK2*1100delC and the common 17 
breast cancer susceptibility variants both individually and summarized in terms of the PRS.7, 8  18 
PATIENTS AND METHODS 19 
Study participants 20 
Female invasive breast cancer patients and healthy controls of European ancestry were included 21 
from studies participating in the Breast Cancer Association Consortium (BCAC)(Table S1). Data from 22 
a study were included if the study provided genotype data of the common variants from at least one 23 
breast cancer patient carrying the 1100delC variant. This selection yielded data from 32 studies and 24 
14 
 
a total of 79,202 study subjects, including 848 CHEK2*1100delC carriers (Table S2) for pairwise 1 
interaction analyses.  Complete quality controlled7, 10 genotype data for all common variants and 2 
CHEK2*1100delC were available from 33,624 study subjects (369 CHEK2*1100delC carriers, Table 3 
S2). This data were used in the analyses involving the PRS. 4 
All participating studies were approved by their institutional review committees. Each study 5 
followed national guidelines for participant inclusion and informed consent procedures. 6 
Genotyping 7 
All variants except CHEK2*1100delC were genotyped centrally using a custom Illumina iSelect 8 
genotyping array (iCOGS, Illumina, Inc. San Diego, CA, USA) as part of the COGS consortium studies 9 
as described earlier.7, 8 CHEK2*1100delC was primarily genotyped using a custom made TaqMan 10 
assay (Applied Biosystems, Foster City, CA, USA), with a small minority being genotyped using 11 
iPLEX.10 In addition to the 38,549 study subjects genotyped using the iCOGS array, 40,653 BCAC 12 
study subjects were genotyped for up to 25 of the common risk variants and these data were used in 13 
the pairwise interaction analysis (Table S2, Table S3). These samples were genotyped by 14 
independent studies following BCAC genotyping standards as described previously.11, 12 15 
Statistical analyses 16 
Statistical analyses were performed using Stata SE 10 (StataCorp, Texas, USA) and R version 2.15.2.13 17 
For the common variants a log-additive model was assumed; i.e. the risk was analyzed in terms of 18 
the number of disease-associated alleles [0,1,2] carried. CHEK2*1100delC was assumed to follow a 19 
dominant inheritance model as the number of rare homozygotes was small (n=19). All analyses were 20 
adjusted for study and seven principal components defined on the basis of the genome-wide data 21 
from the iCOGS project as described previously.7 All reported tests were two-sided. 22 
Polygenic risk score 23 
15 
 
In order to investigate the combined effects of common variants and CHEK2*1100delC, a polygenic 1 
risk score (PRS) based on the main effects of the common variants was calculated using the formula: 2 
i
n
i
i ORa
1
2log   3 
where n is the number of loci included in the model, a is the number of susceptibility alleles in locus i 4 
and OR is the per allele odds ratio for breast cancer, estimated separately for each variant in the 5 
whole data set (Table S4a, column “All”). Results using a PRS based on previously reported ORs7, 8 6 
were essentially identical (data not shown). The PRS was approximately normally distributed in all 7 
study subgroups, and was standardized by mean and standard deviation of the PRS among the 8 
healthy individuals.8 For pairs of linked variants with r2>0.75, we included in the PRS only the lead 9 
variant (rs2981579, not rs2981582; rs12662670, not rs3757318; rs554219, not rs614367). We 10 
excluded two variants (rs78540526 and rs75915166) included in the PRS of Mavaddat et al.8, which 11 
were not genotyped on the iCOGS array, as well as rs17879961, the CHEK2 missense variant I157T, 12 
because the number of study subjects carrying both 1100delC and I157T was very low (n=5).  Thus, 13 
the resulting PRS included 74 variants. The interaction between PRS and CHEK2*1100delC was 14 
assessed by comparing nested logistic regression models: a model including the PRS and 1100delC 15 
genotype and a model supplemented with an interaction term, coded as the product of the PRS and 16 
1100delC. In analyses of the PRS and positive family history of breast cancer, positive family history 17 
was defined as at least one first degree relative with breast cancer. 18 
The cumulative life-time breast cancer risk of CHEK2*1100delC carriers in different PRS-percentiles 19 
was derived assuming an average life-time risk of 22% for CHEK2*1100delC carriers14 and previously 20 
published relative risk estimates associated with the PRS.8  21 
Pairwise interaction analyses 22 
We tested for pairwise interaction between each common variant and CHEK2*1100delC as 23 
described above for the interaction between the PRS and 1100delC. P-values were corrected for 77 24 
parallel tests using the Benjamini-Hochberg method.15 The OR for breast cancer was estimated 25 
16 
 
separately for each of the common variants for the whole dataset and for the subgroup of 1100delC 1 
carriers. These analyses were also performed separately on a subgroup of breast cancer patients 2 
with ER+ disease, because 1100delC is associated with ER+ breast cancer.10 We tested for 3 
heterogeneity in the ORs among different BCAC studies by including an interaction term between 4 
variant and the study, separately for each variant. No significant heterogeneity was found for any 5 
variant (data not shown). Statistical power was estimated as previously suggested for risk interaction 6 
analyses.16 7 
RESULTS 8 
We analyzed the combined effects of CHEK2*1100delC and common low penetrance breast cancer 9 
risk variants using data from the international Breast Cancer Association Consortium (Table S2). The 10 
PRS summarizing the individual effects of 74 common variants was strongly associated with breast 11 
cancer risk among CHEK2*1100delC carriers (OR per unit standard deviation 1.59 [1.21-2.09], 12 
P=0.0008) and the OR was similar to that in non-carriers (1.58 [1.55-1.62], Pinteraction 0.93). ORs for the 13 
highest and lowest quintiles of the PRS distribution were 2.03 [0.86-4.78] and 0.52 [0.16-1.74] for 14 
CHEK2*1100delC carriers, respectively, when compared to the middle quintile (Table 1). Both 15 
estimates were similar to those among non-carriers.  16 
The OR associated with CHEK2*1100delC in the analysis data set 2.99 [2.32–3.85] was attenuated, 17 
when the model was adjusted for positive family history of breast cancer. The OR associated with 18 
the PRS was also slightly attenuated (Table 2). No significant interaction between risk effects 19 
associated with 1100delC, PRS and positive family history was found. However, in a case-only 20 
analysis there was a significant association between the PRS and family history of breast cancer, 21 
among both CHEK2*1100delC carriers (OR 1.29 [1.01-1.65], P=0.04) and non-carriers (OR 1.17 [1.12-22 
1.21], P=4E-16) (Figure S1).  23 
When altogether 77 common variants were considered individually, we found nominally significant 24 
interactions between five variants and CHEK2*1100delC for overall breast cancer (rs11249433, 25 
17 
 
rs11780156, rs204247, rs2981582 and rs704010; Table S4a). Two of these represented synergistic 1 
(more than multiplicative) and three antagonistic interactions (the estimated effect in 1100delC 2 
carriers being in the opposite direction to that in non-carriers). However, none of the interactions 3 
were significant after correction for multiple testing. Nine variants showed a nominally significant 4 
interaction for ER-positive breast cancer (Table S4b).  5 
DISCUSSION 6 
Our analyses on the synergistic effects of CHEK2*1100delC and 77 common low penetrance variants 7 
on breast cancer risk give strong support to the predicted multiplicative polygenic model.8, 17, 18 8 
While this has previously been shown for combinations of low penetrance variants,8 and for variants 9 
in combination with BRCA1 and BRCA2 mutations,19 this is the first direct demonstration for a 10 
“moderate” risk gene and has important implications for risk prediction. The PRS was a significant 11 
risk factor for CHEK2*1100delC carriers, and the estimated OR per unit standard deviation was very 12 
similar in CHEK2*1100delC carriers and in non-carriers, consistent with the hypothesis that the 13 
common susceptibility variants combine with the rare CHEK2*1100delC variant in an approximately 14 
multiplicative fashion. Similarly, the PRS risk estimates for the highest and lowest quintiles did not 15 
differ between the CHEK2*1100delC carriers and non-carriers. These two estimates in the 16 
CHEK2*1100delC carriers alone did not reach statistical significance (Table 1), possibly reflecting 17 
limited statistical power due to the relatively low number of healthy variant carriers (Table S2). 18 
However, this is the largest study genotyped for CHEK2*1100delC and these common variants, and 19 
even though some of the point estimates are not significant, they are consistent with the previous 20 
reports. Most importantly, we did not find evidence for deviation from the multiplicative model, 21 
suggesting that the PRS could be used in risk stratification of 1100delC carriers in a similar manner to 22 
non-carriers. 23 
The unadjusted OR for the CHEK2*110delC variants (Table 2) was higher in our analysis data set than 24 
in previous reports.2, 14 Adjusting for positive family history markedly attenuated the 25 
18 
 
CHEK2*1100delC associated OR, suggestive of some oversampling of familial cases. The PRS OR was 1 
also slightly attenuated after the adjustment. However, CHEK2*1100delC, PRS and family history 2 
remained significant risk factors in the combined model (Table 2) suggesting that the common 3 
variants together explain part of the excess familial risk as previously suggested,17 but that the PRS 4 
has predictive value also in breast cancer families segregating CHEK2*1100delC. 5 
Recently, a large study estimating the risk associated with CHEK2*1100delC in relation to age, tumor 6 
subtype and family history reported the cumulative life-time risk for 1100delC carriers to be about 7 
22%.14 Assuming that the relative effect of the PRS is the same in carriers and non-carriers (OR 8 
higher than 1.48 [1.39-1.57] or lower than 0.65 [0.60–0.70] for percentiles above 80% or lower than 9 
20%, respectively),8 20% of the 1100delC carriers with highest PRS would have life-time risk higher 10 
than 32.6% [30.6%-34.5%] exceeding the threshold for the high-risk category (>30%) according to 11 
the UK NICE guidelines for familial breast cancer.20 Similarly, for the 20% of 1100delC carriers with 12 
lowest PRS, the life-time risk would be lower than 14.3% [13.2%-15.4%], i.e. close to the average 13 
population risk. These observations imply that, if CHEK2*1100delC is to be used in risk prediction, it 14 
can be made more effective by including the PRS, representing the risk modifying effects of common 15 
variants, in the prediction. 16 
CHEK2*1100delC carrier cancers do not represent a phenotypically distinct subgroup of breast 17 
carcinomas. Instead, the phenotypic diversity of CHEK2*1100delC associated cancers resembles that 18 
of breast tumors in general.10 Thus, it was not surprising that the relative risks conferred by the 19 
common variants were similar for the CHEK2*1100delC carriers and for non-carriers, and no 20 
significant pairwise interaction was found. We estimated that we had sufficient statistical power 21 
(80%, at P<0.05) to detect a pairwise interaction between CHEK2*1100delC and any of the common 22 
variants, if the interaction OR was 2.5 or greater, but not enough power to detect interactions 23 
comparable in magnitude to the risk effects associated with the low penetrance variants (OR 1.1-1.5). 24 
Thus, it remains possible that more modest departures from a multiplicative model may exist. If so, 25 
19 
 
however, much larger case-control studies, perhaps combined with pedigree analyses, will be 1 
required to detect them. 2 
In conclusion, our analyses confirm the predicted multiplicative relationship between 3 
CHEK2*1100delC and the common low penetrance variants. Hence, the PRS could be similarly 4 
applied for risk prediction for the variant carriers as for the general population. Most importantly, 5 
the PRS could help identifying the high risk group of the CHEK2*1100delC carriers, who would best 6 
benefit from clinical intervention. 7 
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Table S1. Description of study design and genotype data availability of 32 studies participating in the Breast Cancer Association Consortium (BCAC). 
Abbreviation Study Country Study design Case definition Control definition Samples 
genotyped in 
iCOGS  
(1100delC 
carriers) 
Additional 
BCAC 
samples 
(1100delC 
carriers) 
Genotyped 
and included 
variants 
Ref. 
ABCFS Australian Breast 
Cancer Family Study 
Australia Population-based case-
control study 
All cases diagnosed < age 40 plus a 
random sample of those diagnosed 
ages 40-59 from cancer registries in 
Victoria and New South Wales, plus a 
limited number diagnosed aged 60-69; 
cases living in Melbourne recruited 
from 1992-99 and in Sydney from 
1993-98.  
Identified from the electoral rolls in 
Melbourne from 1992-98 and Sydney 
from 1993-99. Frequency matched to 
cases by age in 5 year categories. 
1240 (5) 710 (1) 77 1 
ABCS Amsterdam Breast 
Cancer Study 
Netherlands Hospital-based 
consecutive cases; 
population-based controls 
All cases (operable, invasive 
mammacarcinoma) aged <50 and 
diagnosed from 1974-1994 in 4 Dutch 
hospitals.  
Random women <50 years of age at 
baseline from 2 population-based 
prospective studies run by National 
Institute for Public Health and the 
Environment, The Netherlands. 
736 (37) 
only cases 
2,515 (69) 24 2 
BBCC Bavarian Breast 
Cancer Cases and 
Controls 
Germany Hospital based cases; 
population based controls 
Consecutive, unselected cases with 
invasive breast cancer recruited at the 
University Breast Centre, Franconia in 
Northern Bavaria during 2002-2010. 
Healthy women with no diagnosis of 
cancer aged 55 or older. Invited by a 
newspaper advertisement in Northern 
Bavaria, and recruited during 2002-
2010. 
8 (0) 
only cases 
1,535 (13) 22 3,4 
 
BBCS British Breast Cancer 
Study 
UK Cancer registry and 
National Cancer Research 
network (NCRN) based 
cases; population based 
controls 
1) English & Scottish Cancer 
Registries: all breast cancer cases who 
developed a first primary before age 65 
in 1971 or later and who subsequently 
developed a second primary cancer.  
2) Unilateral breast cancer cases 
diagnosed before age 70 in 1971 or 
later.  
1) A friend, sister-in-law, daughter-in-
law or other non-blood relative of 
cases. Recruitment of cases and 
controls began in January 2001. 
222 (2) 
mostly 
controls 
2,328 (25) 25 5,6 
BIGGS Breast Cancer in 
Galway Genetic 
Study 
Ireland Hospital based cases; 
population based controls 
Unselected cases recruited from West 
of Ireland since 2001. Cases were 
recruited from University College 
Hospital Galway and surrounding 
hospitals  
Women > 60 years with no personal 
history of any cancer and no family 
History of breast or ovarian cancer 
were identified from retirement groups 
in the West of Ireland (same catchment 
area as cases) during the period 2001-
2008. 
1,462 (3) 49 (0) 77 7,8 
BSUCH Breast Cancer Study 
of the University of 
Heidelberg 
Germany Hospital based cases; 
healthy blood donator 
controls 
All cases diagnosed with breast cancer 
in 2007-2009 at the University 
Women`s Clinic Heidelberg  
Healthy, unrelated, ethnically matched 
female blood donors recruited in 2007 
& 2009 by German Red Cross Blood 
Service of Baden-Württemberg-
Hessen, Institute of Transfusion 
Medicine & Immunology, Mannheim.  
1,051 (12) 887 (7) 77  
 2 
 
CGPS Copenhagen General 
Population Study 
Denmark Population-based Consecutive, incident cases from 1 
hospital with centralized care for a 
population of 400,000 women from 
2001 to the present.  
Community controls residing in the 
same region as cases and with no 
history of breast cancer were identified 
from the Copenhagen General 
Population Study recruited 2003-2007. 
All controls were known to still be 
breast cancer-free at the end of 2007. 
1,953 (29) 
only cases 
6,535 (44) 24 9,10 
ESTHER ESTHER Breast 
Cancer Study 
Germany Population-based case-
control study 
State-wide recruitment of breast 
cancer cases in all hospitals in 
Saarland/Germany in 2001-2003 
State-wide recruitment of participants 
of a routine health check-up in 
Saarland/Germany in 2000-2002. A 
stratified random sample, matched to 
the cases by five year age groups, was 
selected as controls. 
948 (5) 26 (0) 77 11 
GC-HBOC German Consortium 
for Hereditary Breast 
& Ovarian Cancer 
Germany Population-based familial 
case-control study 
Index patients from German breast 
cancer families; BRCA1/2 mutation 
free, collected 1996-2007 via Institute 
of Human Genetics, University 
Heidelberg & Department of 
Gynaecology & Obstetrics, Cologne & 
Department of Gynaecology and 
Obstetrics at the Ludwig-Maximilians-
University, Munich; Germany. 
Healthy, unrelated, ethnically matched 
female blood donors recruited in 2004 
& 2007 by German Red Cross Blood 
Service of Baden-Württemberg-
Hessen, Institute of Transfusion 
Medicine & Immunology, Mannheim. 
72 (0) 
only controls 
1884 (20) 18 12,13 
GENICA Gene Environment 
Interaction and 
Breast Cancer in 
Germany 
Germany Population-based case-
control study 
Incident breast cancer cases enrolled 
between 2000 and 2004 from the 
Greater Bonn area (by of the hospitals 
within the study region); all enrolled 
within 6 months of diagnosis 
Selected from population registries 
from 31 communities in the greater 
Bonn area; matched to cases in 5-year 
age classes between 2001 and 2004 
889 (10) 1128 (8) 77 14,15 
GESBC Genetic 
Epidemiology Study 
of Breast Cancer by 
Age 50 
Germany Population-based study of 
women <50 years 
All incident cases diagnosed <50 years 
of age in 1992-5 in two regions: Rhein-
Neckar-Odenwald and Freiburg, by 
surveying the 38 clinics serving these 
regions 
Selected from random lists of residents 
of the study regions supplied by 
population registries; two controls were 
selected for each case, matched by 
age and study region. Recruitment was 
carried out 1992-1998. 
 725 (2) 22 16 
HABCS Hannover Breast 
Cancer Study 
Germany Hospital-based case-
control study 
Cases who received radiotherapy for 
breast cancer at Hannover  Medical 
School between 1997-2003, 
unselected for age or family history 
Anonymous female blood bank donors 
at Hannover  Medical School, collected 
from 8/2005-12/2005, with known age 
and ethnic background 
 2,037 (27) 23 17 
HEBCS Helsinki Breast 
Cancer Study 
Finland Hospital-based case-
control study + additional 
familial cases  
1) Consecutive cases (883) from the  
Department of Oncology, Helsinki 
University Central Hospital 1997-8 and 
2000 
2) Consecutive cases (986) from the 
Department of Surgery, Helsinki 
University Central Hospital 2001 – 
2004 
3) Familial breast cancer patients (536) 
from the Helsinki University Central 
Hospital, Departments of Oncology 
and Clinical Genetics (1995-) 
Healthy females from the same 
geographical region in Southern 
Finland in 2003. 
2,549 (62) 748 (33) 77 18-20 
 3 
 
HMBCS Hannover-Minsk 
Breast Cancer Study 
Belarus Hospital based cases; 
population based controls 
Ascertainment at the Byelorussian 
Institute for Oncology and Medical 
Radiology Aleksandrov N.N. in Minsk 
or at one of 5 regional oncology 
centres in Gomel, Mogilev, Grodno, 
Brest or Vitebsk through the years 
2002-2008. 
Controls from the same population 
aged 18-72 years. Healthy female 
probands recruited from the same 
geographical regions as cases during 
the years 2002-2008. About 75% of 
controls were women invited for 
general medical examination at five 
regional gynaecology clinics and 
cancer-free volunteers ascertained at 
the Institute for Inherited Diseases in 
Minsk; 20% were cancer-free female 
blood bank donors recruited at  
Republic Blood Bank, Minsk, Belarus; 
finally 5% of controls were healthy 
cancer-free relatives of some breast 
cancer patients. 
772 (4) 1,750 (10) 77 21 
HUBCS Hannover-Ufa Breast 
Cancer Study 
Russia Hospital based cases; 
population based controls 
Consecutive Russian breast cancer 
patients aged 24-86 years ascertained 
at one of the two participating 
oncological centres in Bashkorstostan 
and Siberia through the years 2000-
2008  
Population controls aged 18-84 years 
recruited from a population study of 
different populations of Russia. Healthy 
volunteers (without any malignancy) 
were selected from the same 
geographical regions during the years 
2002-2008. 
 2,394 (6) 18 21 
KARBAC Karolinska Breast 
Cancer Study 
Sweden Population and hospital-
based cases; 
geographically matched 
controls 
1. Familial cases from Department of 
Clinical Genetics, Karolinska University 
Hospital, Stockholm.     
2. Consecutive cases from Department 
of Oncology, Huddinge & Söder 
Hospital, Stockholm 1998-2000  
Blood donors of mixed gender from 
same geographical region. Excess 
material was received from all blood 
donors over a 3 month period in 2004 
(approximately 3000) and DNA was 
extracted from a random sample of 
1500 
1,373 (12) 222 (4) 77 22,23 
KBCP Kuopio Breast 
Cancer Project 
Finland Population-based 
prospective clinical cohort 
Women seen at Kuopio University 
Hospital between 1990 and 1995 
because of breast lump, 
mammographic abnormality, or other 
breast symptom who were found to 
have breast cancer 
Age and long-term area-of-residence 
matched controls selected from the 
National Population Register and 
interviewed in parallel with the cases 
614 (12) 216 (5) 77 24,25 
kConFab/ 
AOCS 
Kathleen Cuningham 
Foundation 
Consortium for 
research into Familial 
Breast 
Cancer/Australian 
Ovarian Cancer 
Study 
Australia and 
New Zealand 
Clinic-based recruitment of 
familial breast cancer 
patients (cases);  
population-based case-
control study of ovarian 
cancer (controls only) 
Cases were from multiple-case breast 
and breast-ovarian families recruited 
though family cancer clinics from 
across Australia and New Zealand 
from 1998 to the present. Cases were 
selected for inclusion in BCAC studies 
if (i) family was negative for mutations 
in BRCA1 and BRCA2 (ii) case was 
the index for the family, defined as 
youngest breast cancer affected family 
member. 
Female controls were ascertained by 
the Australian Ovarian Cancer Study 
identified from the electoral rolls from 
all over Australia from 2002-2006. 
1,145 (12) 160 (0) 77 26,27 
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LMBC Leuven 
Multidisciplinary 
Breast Centre 
Belgium Hospital-based case-
control study 
All patients diagnosed with breast 
cancer and seen in the 
Multidisciplinary Breast Centre in 
Leuven (Gashuisberg) since June 
2007 plus retrospective collection of 
cases diagnosed since 2000 
Healthy controls (blood donors) 
collected at the Red Cross and located 
in Gasthuisberg hospital (Oct-2007-
March 2008) 
1,609 (12) 87 (1) 77 28,29 
MCBCS Mayo Clinic Breast 
Cancer Study 
USA Hospital-based case-
control study 
Incident cases residing in 6 states 
(MN, WI, IA, IL, ND, SD) seen at the 
Mayo Clinic in Rochester, MN from 
2002-5 
Women without cancer presenting for 
general medical examination at the 
Mayo Clinic. Controls were recruited 
concurrently with cases and were 
frequency matched to cases on age, 
ethnicity and county/state 
1,663 (15) 524 (6) 77 30 
MCCS Melbourne 
Collaborative Cohort 
Study 
Australia Population-based 
prospective cohort study 
Incident cases diagnosed within the 
Melbourne Collaborative Cohort Study 
during the follow-up from baseline 
(1990-1994) to 2008 of the 24469 
participating women 
Random sample of the initial cohort 538 (4) 479 (3) 77 31 
NBCS Norwegian Breast 
Cancer Study 
Norway Hospital-based case-
control study 
Incidence cases from three different 
hospitals:  
1) Cases  (114)  mean age  64 (28-92) 
at Ullevål Univ. Hospital 1990-94 
2) cases (182) mean age 59 (26-75) 
referred to Norwegian Radium Hospital  
1975-1986 
3)  cases (124), mean age 56 (29-82) ) 
with stage I or II disease, in the Oslo 
micro-metastases study at Norwegian 
Radium Hospital between 1995-1998, 
4)  cases (71)  mean age 67 (37–82)  
with locally advanced disease at 
Haukeland Univ. Hospital. 
Control subjects were healthy women, 
age 55-71, residing in Tromsø (440), 
and Bergen (109) attending the 
Norwegian Breast Cancer Screening 
Program.  
81 (0) 2,453 (12) 17 32 
NC-BCFR Northern California 
Breast Cancer 
Family Registry 
USA Population-based familial 
case-control study 
Cases included those enrolled in the 
NC-BCFR as part of Phase I and II 
recruitment. Incident cases aged <65 
years diagnosed between 1995 and 
2003 were identified through the SEER 
cancer registry of the Greater San 
Francisco Bay Area. All cases likely at 
increased genetic risk were eligible to 
enrol in the BCFR (dx at age <35 yrs, 
personal history of ovarian or 
childhood cancer, bilateral breast 
cancer with 1st dx at age <50, family 
history of breast or ovarian cancer in 
first-degree relatives). Cases not 
meeting these criteria were randomly 
sampled (2.5% of whites, 30% of 
African Americans, 28% of Hispanics, 
38% of Asian Americans).  
Controls were identified through 
random digit dialling conducted from 
1999-2000 in the same geographic 
region. Controls were frequency 
matched to cases on 5-year age group 
and race/ethnicity, at a ratio of 1 
control per 2 cases.  
 421 (7) 24 33 
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OFBCR Ontario Familial 
Breast Cancer 
Registry 
Canada Population-based familial 
case-control study  
Invasive cases (all aged 20-54 years 
and a random sample aged 55-69 
years) were identified from the Ontario 
Cancer Registry 1996-1998. All those 
at high genetic risk (family history of 
specific cancers particularly breast and 
ovarian, early onset disease, 
Ashkenazi ethnicity or a diagnosis of 
multiple breast cancer) were eligible. 
Random samples of women not 
meeting these criteria were also asked 
to participate. During 2001-2005, some 
enrolment continued, but was limited to 
minority and high-risk families. 
Unrelated, unaffected population 
controls were recruited between 2003-
2005 by calling randomly selected 
residential telephone numbers 
throughout the same geographical 
region. Eligible controls were women 
with no history of breast cancer and 
were frequency-matched by 5-year age 
group to the expected age distribution 
of cases. Approximately, 65% of 
identified eligible women returned 
questionnaires, and 63% of these 
donated a blood specimen. 
1,345 (11) 103 (0) 77 33 
ORIGO Leiden University 
Medical Centre 
Breast Cancer Study 
Netherlands Hospital-based 
prospective cohort study 
Consecutive cases diagnosed 1996-
2006 in 2 hospitals of South-West 
Netherlands (Leiden & Rotterdam). No 
selection for family history; Rotterdam 
cases selected for diagnosis aged <70. 
Cases with in situ carcinomas eligible. 
Three groups of controls: 
1) Blood bank healthy donors from 
Southwest Netherlands recruited  in 
1996, 2000 or 2007 
2) People who married a person who 
was part of a family with high breast 
cancer risk (BRCA1/2/x). From the 
Southwest of the Netherlands, 
recruited 1990-1996 
3) Females tested at the local clinical 
genetics department for familial 
diseases, excluding familial cancer 
syndromes (no mutation found in 
gene(s) related to the disease being 
tested), recruited 1995-2007. 
178 (6) 
only cases 
449 (17) 10 34,35 
PBCS NCI Polish Breast 
Cancer Study 
Poland Population-based case-
control study 
Incident cases from 2000-2003 
identified through a rapid identification 
system in participating hospitals 
covering ~ 90% of all eligible cases, 
and cancer registries in Warsaw and 
Łódź covering 100% of all eligible 
cases 
Randomly selected from population 
lists of all residents of Poland, stratified 
and frequency matched to cases by 
case city and age in 5 year categories. 
Recruited 2000-2003. 
934 (6) 3,175 (10) 77 36 
RBCS Rotterdam Breast 
Cancer Study 
Netherlands Hospital based case-
control study, Rotterdam 
area 
Familial breast cancer patients 
selected from the clinical genetics 
centre at Erasmus Medical Centre; 
recruited 1994 - 2005 
Spouses or mutation-negative siblings 
of heterozygous Cystic Fibrosis 
mutation carriers selected from the 
clinical genetics centre at Erasmus 
Medical Centre; recruited 1996 - 2006 
1,313 (54) 118 (2) 77 37 
SASBAC Singapore and 
Sweden Breast 
Cancer Study 
Sweden Population-based case-
control study 
Incident cases from October 1993 to 
March 1995 identified via the 6 
regional cancer registries in Sweden, 
to which reporting is mandatory. 
Controls were randomly selected from 
the total population registry in 5-year 
age groups to match the expected age-
frequency distribution among cases. 
Patients and controls were recruited 
from Oct 1993 through April 1995. 
2,424 (20) 69 (1) 77 38 
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SBCS Sheffield Breast 
Cancer Study 
UK Hospital-based case-
control study  
Women with pathologically confirmed 
breast cancer recruited from surgical 
outpatient clinics at the Royal 
Hallamshire Hospital, Sheffield, 1998 – 
2005; cases are a mixture of prevalent 
and incident disease 
Unselected women attending the 
Sheffield Mammography Screening 
Service between Sep 2000 - Aug 2004, 
if their mammograms showed no 
evidence of a breast lesion  
1,536 (13) 273 (1) 77 39,40 
SEARCH Study of 
Epidemiology and 
Risk factors in 
Cancer Heredity 
UK Population-based case-
control study 
2 groups of cases identified through 
East Anglian Cancer Registry: 
1)  prevalent cases diagnosed 1991-
1996 under 55 years of age at 
diagnosis, recruited 1996-2002 
2) incident cases diagnosed since 
1996 under 70 years of age at 
diagnosis, recruited 1996-present. 
Two groups of controls: 
1) selected from the EPIC-Norfolk 
cohort study of 25,000 individuals age 
45-74 recruited between 1992 
and1994, based in the same 
geographic region as cases 
2) selected from GP practices from 
March 2003 to present, frequency 
matched to cases by age and 
geographic region 
11,874 (110) 765 (10) 77 41 
UCIBCS UCI Breast Cancer 
Study 
USA Population-based case-
control study 
All cases diagnosed in Orange County, 
California, during one-year period 
beginning March 1, 1994. Ascertained 
through the population-based Cancer 
Surveillance Program of Orange 
County California  (CSPOC) 
Female controls under age 75 years 
without history of cancer recruited 
using random digit dialing among 
Orange County residents & frequency 
matched to cases by age & 
race/ethnicity. Recruited from 1998-
2003 
 1,287 (10) 23 42,43 
UKBGS UK Breakthrough 
Generations Study 
UK Prospective cohort study: 
nested case-control study 
of women who had had 
breast cancer prior to 
entry into the cohort 
All members who had had breast 
cancer before entry into the 
Breakthrough Generations Study 
(cohort of 100,000+ women followed 
up for breast cancer, recruited from the 
UK during 2003-2009). 
Women who had not had breast 
cancer before entry into the cohort 
study, 1:1 matched to cases on date of 
birth, year of entry into the study 
(2003-2009), source of recruitment, 
blood sample and ethnicity  
20 (0) 4,601 (38) 22  
Note: Genotype data was included from individual studies on a per locus basis. Genotype data from each study and each variant was included in the analyses, if the study 
provided genotype data from at least one invasive breast cancer patients carrying CHEK2*1100delC. 
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Table S2. CHEK2*1100delC genotype data availability for breast cancer (BC) cases and controls. 
  
All 
BC cases 
1100delC 
BC cases 
All 
controls 
1100delC 
controls 
All 
subjects 
1100delC 
subjects 
iCOGS subjectsa 21,375 368 17,174 88 38,549 456 
Additional BCAC subjectsa 17,764 256 22,889 136 40,653 392 
Total number of subjectsa 39,139 624 40,063 224 79,202 848 
Subjects with complete datab 17,640 285 15,984 84 33,624 369 
 
a 
Data for pairwise interaction analyses was included on a per variant basis and came from two sources: iCOGS genotyping 
array (data on 76 variants) and earlier BCAC studies (data on 25 variants).  
b 
For all analyses involving the polygenic risk score, only study subjects with complete quality controlled data on all 76 
variants were included. Complete data was available from altogether 33,624 study subjects. 
 
 1 
 
Table S3. Description of genotype data coverage and genotyping methods for each low penetrance variant. 
 Variant 
Number of 
samples 
from 
iCOGS
1-3
 
Number of 
additional 
BCAC 
samples 
Genotyping methods for additional BCAC samples 
a
rs1045485 / 
rs17468277 38,435 31,218 
rs1045485: TaqMan, Sequenom iPLEX, illumina, Amplifluor, SNPstream, 
                      RFLP, MALDI-TOF MS, ARMS 
rs17468277: TaqMan, Sequenom MassArray and iPLEX
4
 
a
rs999737 /  
rs10483813 38,217 34,769 
rs999737: TaqMan, Sequenom MassArray and iPLEX 
rs10483813: TaqMan, Sequenom MassArray and iPLEX
5
 
rs10069690 35,258     
rs1011970 38,363 34,201 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
6
 
rs10472076 35,273     
rs10759243 35,269     
rs10771399 38,348 30,917 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
7
 
rs10941679 38,210 38,587 TaqMan, Sequenom MassArray and iPLEX
8
 
rs10995190 38,367 34,824 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
6
 
rs11075995 35,269     
rs11199914 35,275     
rs11242675 35,254     
rs11249433 38,212 34,811 TaqMan, Sequenom MassArray and iPLEX
5
 
rs11552449 35,276     
rs11571833 35,279     
rs11780156 35,271     
rs11814448 35,279     
rs11820646 35,274     
rs12422552 35,273     
rs12493607 35,268     
rs12662670 38,548 20,180 TaqMan, Sequenom MassArray and iPLEX
9
 
rs12710696 35,274     
rs1292011 37,618 28,903 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
7
 
rs132390 35,278     
rs13281615 37,562 23,553 TaqMan, Sequenom MassArray and iPLEX
10
 
rs13329835 35,277     
rs13387042 38,449 35,998 TaqMan, Sequenom MassArray and iPLEX
11
 
rs1353747 35,279     
rs1432679 35,221     
rs1436904 35,268     
rs1550623 35,262     
rs16857609 35,269     
rs17356907 35,244     
rs17529111 35,270     
rs17817449 35,275     
rs2016394 35,132     
rs204247 35,275     
rs2046210 38,183 28,722 TaqMan, Sequenom MassArray and iPLEX
9
 
rs2236007 35,272     
rs2363956 37,301 15,997 TaqMan, Sequenom MassArray and iPLEX
12
 
rs2380205 38,366 34,234 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
6
 
rs2588809 35,276     
rs2736108 35,260     
rs2823093 38,368 34,004 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
7
 
rs2943559 34,977     
rs2981579 35,277     
rs2981582 38,543 35,382 TaqMan, Sequenom MassArray and iPLEX
10
 
rs3757318 38,547   
rs3760982 35,243     
rs3803662 38,463 28,204 TaqMan, Sequenom MassArray and iPLEX
10
 
rs3817198 38,373 27,067 TaqMan, Sequenom MassArray and iPLEX
10
 
rs3903072 35,266     
rs4245739 35,276     
rs4808801 35,255     
 2 
 
rs4849887 35,277     
rs4973768 38,395 34,683 TaqMan, Sequenom MassArray and iPLEX
13
 
rs527616 35,279     
rs554219 35,269     
rs6001930 35,279     
rs614367 36,413 26,730 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
6
 
rs616488 35,271     
rs6472903 35,223     
rs6504950 38,467 36,006 TaqMan, Sequenom MassArray and iPLEX
12
 
rs6678914 35,275     
rs6762644 35,268     
rs6828523 35,267     
rs704010 38,356 34,720 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
6
 
rs7072776 35,277     
rs720475 35,278     
rs75915166 35,276     
rs7904519 35,251     
rs8170 38,358 29,359 TaqMan, Sequenom MassArray and iPLEX
12
 
rs865686 38,364 30,866 TaqMan, Sequenom MassArray and iPLEX, Fluidigm
14
 
rs889312 38,466 29,822 TaqMan, Sequenom MassArray and iPLEX
10
 
rs941764 35,242     
rs9693444 35,277     
rs9790517 35,271     
a Genotype data of linked variants (r2=1) were combined for all analyses. 
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Table S4. Odds ratios (OR) and 95% confidence intervals (CI) estimated for the whole dataset and for the carriers of 
CHEK2*1100delC, as well as for pairwise interaction between each variant and CHEK2*1100delC for (a) breast cancer (b) 
estrogen receptor positive (ER+) breast cancer.  
 
a] 
 
  ALL 1100delC carriers Interaction Likelihood ratio test 
 
  
major: 
minor OR 95% CI OR 95% CI OR 95% CI p-value 
corrected  
p-value
a
 
 
rs1045485/rs17468277   0.95 [0.92 - 0.97] 0.98 [0.66 - 1.45] 0.96 [0.67 - 1.39] 0.84 0.98 
 
rs999737/rs10483813   0.92 [0.90 - 0.94] 0.72 [0.53 - 0.99] 0.77 [0.58 - 1.03] 0.079 0.61 
 
rs10069690 C:T 1.04 [1.01 - 1.07] 0.99 [0.64 - 1.53] 0.99 [0.65 - 1.49] 0.95 0.98 
 
rs1011970 G:T 1.07 [1.04 - 1.09] 1.17 [0.81 - 1.68] 1.02 [0.73 - 1.43] 0.88 0.98 
 
rs10472076 T:C 1.06 [1.03 - 1.09] 0.73 [0.50 - 1.08] 0.73 [0.50 - 1.05] 0.093 0.65 
 
rs10759243 C:A 1.07 [1.03 - 1.10] 1.11 [0.74 - 1.68] 1.06 [0.72 - 1.56] 0.77 0.98 
 
rs10771399 A:G 0.84 [0.81 - 0.86] 0.72 [0.48 - 1.08] 0.77 [0.53 - 1.12] 0.18 0.96 
 
rs10941679 A:G 1.12 [1.10 - 1.15] 1.27 [0.94 - 1.72] 1.14 [0.87 - 1.51] 0.34 0.97 
 
rs10995190 G:A 0.88 [0.86 - 0.90] 0.90 [0.63 - 1.29] 1.10 [0.79 - 1.53] 0.59 0.98 
 
rs11075995 A:T 1.06 [1.03 - 1.10] 1.67 [1.04 - 2.69] 1.52 [0.98 - 2.36] 0.057 0.61 
 
rs11199914 C:T 0.95 [0.93 - 0.98] 1.23 [0.82 - 1.86] 1.19 [0.81 - 1.75] 0.38 0.97 
 
rs11242675 T:C 0.97 [0.94 - 1.00] 0.80 [0.55 - 1.16] 0.81 [0.57 - 1.15] 0.24 0.96 
 
rs11249433 A:G 1.12 [1.10 - 1.14] 0.80 [0.62 - 1.03] 0.74 [0.59 - 0.94] 0.014 0.54 
 
rs11552449 C:T 1.08 [1.05 - 1.12] 1.43 [0.86 - 2.37] 1.23 [0.77 - 1.97] 0.38 0.97 
 
rs11571833 A:T 1.28 [1.11 - 1.47] 1.75 [0.20 - 15.63] 1.38 [0.17 - 11.47] 0.76 0.98 
 
rs11780156 G:A 1.09 [1.05 - 1.13] 2.16 [1.21 - 3.88] 1.86 [1.07 - 3.22] 0.021 0.54 
 
rs11814448 A:C 1.26 [1.14 - 1.38] 0.52 [0.16 - 1.71] 0.48 [0.16 - 1.47] 0.22 0.96 
 
rs11820646 C:T 0.94 [0.91 - 0.97] 0.87 [0.60 - 1.26] 0.93 [0.66 - 1.30] 0.66 0.98 
 
rs12422552 G:C 1.06 [1.02 - 1.09] 1.29 [0.85 - 1.95] 1.25 [0.85 - 1.85] 0.25 0.96 
 
rs12493607 G:C 1.06 [1.03 - 1.09] 0.97 [0.66 - 1.42] 0.98 [0.69 - 1.40] 0.92 0.98 
rs12662670 A:C 1.14 [1.10 - 1.18] 1.36 [0.73 - 2.56] 1.26 [0.70 - 2.25] 0.44 0.97 
 
rs12710696 C:T 1.05 [1.02 - 1.08] 0.96 [0.66 - 1.41] 0.92 [0.64 - 1.32] 0.64 0.98 
 
rs1292011 A:G 0.93 [0.91 - 0.95] 1.01 [0.75 - 1.35] 1.05 [0.80 - 1.37] 0.73 0.98 
 
rs132390 T:C 1.18 [1.10 - 1.27] 0.96 [0.57 - 1.62] 0.91 [0.56 - 1.46] 0.69 0.98 
 
rs13281615 A:G 1.11 [1.09 - 1.14] 0.85 [0.63 - 1.13] 0.80 [0.61 - 1.05] 0.11 0.65 
 
rs13329835 A:G 1.07 [1.04 - 1.11] 1.14 [0.73 - 1.79] 1.23 [0.81 - 1.88] 0.33 0.97 
 
rs13387042 A:G 1.13 [1.11 - 1.15] 1.12 [0.87 - 1.44] 0.96 [0.76 - 1.21] 0.71 0.98 
 
rs1353747 T:G 0.89 [0.85 - 0.93] 1.09 [0.51 - 2.35] 1.34 [0.66 - 2.75] 0.41 0.97 
 
rs1432679 T:C 1.10 [1.07 - 1.13] 1.12 [0.75 - 1.66] 0.93 [0.65 - 1.34] 0.70 0.98 
 
rs1436904 T:G 0.97 [0.94 - 1.00] 1.17 [0.79 - 1.71] 1.16 [0.80 - 1.67] 0.44 0.97 
 
rs1550623 A:G 0.94 [0.91 - 0.98] 0.85 [0.51 - 1.41] 0.93 [0.58 - 1.49] 0.76 0.98 
 
rs16857609 C:T 1.08 [1.05 - 1.11] 1.30 [0.84 - 2.01] 1.19 [0.80 - 1.78] 0.39 0.97 
 
rs17356907 A:G 0.91 [0.88 - 0.93] 0.83 [0.55 - 1.25] 1.00 [0.68 - 1.47] 1.00 1.00 
 
rs17529111 T:C 1.07 [1.03 - 1.10] 1.14 [0.73 - 1.78] 1.09 [0.71 - 1.67] 0.69 0.98 
 
rs17817449 T:G 0.93 [0.91 - 0.96] 0.89 [0.61 - 1.29] 0.95 [0.67 - 1.35] 0.77 0.98 
 
rs2016394 G:A 0.95 [0.92 - 0.97] 1.05 [0.74 - 1.48] 1.07 [0.77 - 1.48] 0.70 0.98 
 
rs204247 A:G 1.05 [1.02 - 1.08] 0.70 [0.49 - 1.00] 0.64 [0.46 - 0.89] 0.007 0.54 
 
rs2046210 G:A 1.09 [1.07 - 1.12] 1.04 [0.77 - 1.39] 0.95 [0.72 - 1.24] 0.69 0.98 
 
rs2236007 G:A 0.93 [0.89 - 0.96] 1.20 [0.77 - 1.88] 1.10 [0.74 - 1.65] 0.64 0.98 
 
rs2363956 A:C 0.98 [0.95 - 1.00] 1.26 [0.92 - 1.73] 1.29 [0.97 - 1.71] 0.074 0.61 
 
rs2380205 C:T 0.98 [0.96 - 1.00] 1.02 [0.79 - 1.33] 1.03 [0.81 - 1.30] 0.82 0.98 
 
rs2588809 C:T 1.07 [1.03 - 1.11] 1.13 [0.65 - 1.95] 1.26 [0.75 - 2.13] 0.37 0.97 
 
rs2736108 C:T 0.93 [0.91 - 0.96] 0.95 [0.64 - 1.43] 1.04 [0.71 - 1.53] 0.83 0.98 
 
rs2823093 G:A 0.93 [0.91 - 0.95] 0.83 [0.62 - 1.12] 0.85 [0.65 - 1.12] 0.25 0.96 
 
rs2943559 A:G 1.14 [1.09 - 1.21] 1.30 [0.62 - 2.71] 1.17 [0.59 - 2.32] 0.64 0.98 
 
rs2981579 G:A 1.25 [1.22 - 1.29] 1.40 [0.95 - 2.04] 1.02 [0.71 - 1.45] 0.92 0.98 
 
rs2981582 G:A 1.26 [1.23 - 1.28] 1.68 [1.28 - 2.20] 1.29 [1.00 - 1.67] 0.044 0.61 
rs3757318 G:A 1.15 [1.10 - 1.20] 1.71 [0.66 - 4.42] 1.55 [0.63 - 3.82] 0.31 0.97 
 
rs3760982 G:A 1.06 [1.03 - 1.09] 1.19 [0.83 - 1.71] 1.10 [0.78 - 1.55] 0.59 0.98 
 
rs3803662 G:A 1.24 [1.22 - 1.27] 1.17 [0.87 - 1.56] 1.01 [0.77 - 1.33] 0.93 0.98 
 
rs3817198 T:C 1.06 [1.04 - 1.09] 1.12 [0.84 - 1.50] 0.98 [0.75 - 1.28] 0.89 0.98 
 
rs3903072 G:T 0.94 [0.92 - 0.97] 0.97 [0.66 - 1.41] 0.94 [0.66 - 1.33] 0.72 0.98 
 
rs4245739 A:C 1.03 [1.00 - 1.06] 1.06 [0.66 - 1.69] 1.05 [0.68 - 1.63] 0.81 0.98 
 
rs4808801 A:G 0.92 [0.89 - 0.95] 0.65 [0.44 - 0.96] 0.72 [0.50 - 1.02] 0.067 0.61 
 
rs4849887 C:T 0.92 [0.88 - 0.97] 1.00 [0.52 - 1.95] 1.04 [0.56 - 1.94] 0.90 0.98 
 
rs4973768 C:T 1.09 [1.07 - 1.11] 1.13 [0.87 - 1.47] 0.98 [0.77 - 1.24] 0.88 0.98 
 
rs527616 G:C 0.95 [0.92 - 0.97] 1.04 [0.71 - 1.53] 1.20 [0.84 - 1.70] 0.32 0.97 
 
rs554219 C:G 1.26 [1.21 - 1.32] 1.21 [0.67 - 2.19] 0.99 [0.56 - 1.75] 0.98 0.99 
 
rs6001930 T:C 1.12 [1.08 - 1.17] 0.84 [0.50 - 1.40] 0.74 [0.45 - 1.19] 0.22 0.96 
 
rs614367 C:T 1.20 [1.17 - 1.24] 1.28 [0.86 - 1.89] 1.02 [0.70 - 1.49] 0.91 0.98 
 
rs616488 A:G 0.94 [0.91 - 0.97] 0.92 [0.61 - 1.39] 1.05 [0.72 - 1.54] 0.80 0.98 
 
rs6472903 T:G 0.92 [0.89 - 0.95] 0.78 [0.48 - 1.26] 0.79 [0.51 - 1.23] 0.30 0.97 
 
rs6504950 G:A 0.93 [0.91 - 0.95] 1.01 [0.76 - 1.36] 1.09 [0.83 - 1.42] 0.54 0.98 
 
rs6678914 G:A 0.98 [0.95 - 1.00] 1.14 [0.78 - 1.67] 1.15 [0.81 - 1.64] 0.44 0.97 
 
rs6762644 A:G 1.06 [1.03 - 1.09] 1.09 [0.75 - 1.60] 0.94 [0.67 - 1.32] 0.71 0.98 
 
rs6828523 C:A 0.89 [0.86 - 0.93] 0.77 [0.43 - 1.40] 0.87 [0.51 - 1.51] 0.63 0.98 
 
rs704010 C:T 1.07 [1.05 - 1.10] 0.85 [0.66 - 1.10] 0.78 [0.62 - 0.99] 0.042 0.61 
 
rs7072776 G:A 1.07 [1.04 - 1.10] 1.44 [0.92 - 2.25] 1.23 [0.82 - 1.85] 0.30 0.97 
 
rs720475 G:A 0.92 [0.89 - 0.95] 0.71 [0.46 - 1.10] 0.78 [0.53 - 1.16] 0.22 0.96 
 
rs75915166 C:A 1.34 [1.26 - 1.41] 1.97 [0.77 - 5.05] 1.54 [0.62 - 3.79] 0.33 0.97 
 
rs7904519 A:G 1.07 [1.04 - 1.10] 1.15 [0.80 - 1.66] 1.09 [0.78 - 1.54] 0.61 0.98 
 
rs8170 G:A 1.03 [1.00 - 1.05] 0.82 [0.59 - 1.13] 0.78 [0.58 - 1.06] 0.11 0.65 
 
rs865686 T:G 0.89 [0.87 - 0.90] 0.83 [0.64 - 1.10] 0.97 [0.76 - 1.25] 0.82 0.98 
 
rs889312 A:C 1.10 [1.08 - 1.13] 0.92 [0.69 - 1.22] 0.79 [0.61 - 1.02] 0.073 0.61 
 
rs941764 A:G 1.05 [1.02 - 1.09] 0.94 [0.65 - 1.36] 0.99 [0.70 - 1.40] 0.94 0.98 
 
rs9693444 C:A 1.06 [1.03 - 1.09] 1.24 [0.84 - 1.84] 1.08 [0.75 - 1.56] 0.67 0.98 
 
rs9790517 C:T 1.04 [1.00 - 1.07] 0.93 [0.59 - 1.44] 0.92 [0.60 - 1.39] 0.68 0.98 
 
 
b] 
 
  
ALL ER+ ER+ 1100delC 
carriers 
Interaction Likelihood ratio test 
 
  
major: 
minor OR 95% CI OR 95% CI OR 95% CI p-value 
corrected  
p-value
a
 
 
rs1045485/rs17468277   0.96 [0.93 - 1.00] 1.18 [0.73 - 1.92] 1.02 [0.66 - 1.57] 0.94 0.99 
 
rs999737/rs10483813   0.92 [0.89 - 0.95] 0.78 [0.54 - 1.15] 0.83 [0.59 - 1.17] 0.28 0.91 
 
rs10069690 C:T 1.02 [0.99 - 1.06] 0.95 [0.59 - 1.53] 0.95 [0.61 - 1.47] 0.80 0.99 
 
rs1011970 G:T 1.07 [1.03 - 1.10] 0.97 [0.63 - 1.51] 0.88 [0.60 - 1.29] 0.50 0.97 
 
rs10472076 T:C 1.05 [1.02 - 1.09] 0.78 [0.51 - 1.19] 0.76 [0.51 - 1.11] 0.16 0.88 
 
rs10759243 C:A 1.09 [1.05 - 1.12] 0.92 [0.59 - 1.45] 0.92 [0.62 - 1.38] 0.70 0.98 
 
rs10771399 A:G 0.86 [0.82 - 0.89] 0.83 [0.51 - 1.34] 0.80 [0.51 - 1.24] 0.32 0.91 
 
rs10941679 A:G 1.16 [1.13 - 1.19] 1.43 [1.00 - 2.04] 1.26 [0.91 - 1.73] 0.16 0.88 
 
rs10995190 G:A 0.88 [0.85 - 0.91] 0.95 [0.61 - 1.46] 1.22 [0.83 - 1.81] 0.31 0.91 
 
rs11075995 A:T 1.04 [1.00 - 1.08] 1.65 [0.99 - 2.75] 1.59 [0.99 - 2.54] 0.047 0.46 
 
rs11199914 C:T 0.94 [0.91 - 0.97] 1.23 [0.78 - 1.93] 1.20 [0.80 - 1.82] 0.38 0.91 
 
rs11242675 T:C 0.98 [0.95 - 1.01] 0.75 [0.49 - 1.13] 0.74 [0.51 - 1.07] 0.11 0.77 
 
rs11249433 A:G 1.14 [1.11 - 1.17] 0.71 [0.53 - 0.96] 0.67 [0.51 - 0.87] 0.0030 0.23 
 
rs11552449 C:T 1.10 [1.05 - 1.14] 1.42 [0.83 - 2.45] 1.24 [0.76 - 2.02] 0.38 0.91 
 
rs11571833 A:T 1.34 [1.14 - 1.57] 1.93 [0.21 - 18.08] 1.22 [0.14 - 10.77] 0.86 0.99 
 
rs11780156 G:A 1.11 [1.06 - 1.15] 2.49 [1.31 - 4.73] 2.18 [1.21 - 3.92] 0.0060 0.23 
 
rs11814448 A:C 1.24 [1.11 - 1.38] 0.63 [0.18 - 2.23] 0.65 [0.20 - 2.07] 0.47 0.97 
 
rs11820646 C:T 0.94 [0.91 - 0.97] 0.92 [0.62 - 1.38] 0.97 [0.67 - 1.39] 0.85 0.99 
 
rs12422552 G:C 1.06 [1.02 - 1.10] 1.40 [0.89 - 2.20] 1.30 [0.85 - 1.97] 0.22 0.91 
 
rs12493607 G:C 1.06 [1.03 - 1.10] 0.96 [0.64 - 1.45] 0.97 [0.67 - 1.40] 0.86 0.99 
rs12662670 A:C 1.10 [1.05 - 1.15] 1.86 [0.88 - 3.90] 1.76 [0.89 - 3.48] 0.094 0.77 
 
rs12710696 C:T 1.03 [1.00 - 1.06] 0.85 [0.56 - 1.30] 0.85 [0.58 - 1.26] 0.43 0.97 
 
rs1292011 A:G 0.91 [0.88 - 0.93] 1.02 [0.71 - 1.47] 1.15 [0.84 - 1.57] 0.38 0.91 
 
rs132390 T:C 1.17 [1.08 - 1.28] 1.10 [0.61 - 1.98] 0.99 [0.59 - 1.66] 0.98 0.99 
 
rs13281615 A:G 1.11 [1.08 - 1.14] 0.73 [0.52 - 1.00] 0.74 [0.55 - 1.00] 0.048 0.46 
 
rs13329835 A:G 1.08 [1.04 - 1.12] 1.18 [0.72 - 1.92] 1.24 [0.80 - 1.94] 0.33 0.91 
 
rs13387042 A:G 1.14 [1.11 - 1.16] 1.35 [0.98 - 1.85] 1.05 [0.79 - 1.39] 0.74 0.99 
 
rs1353747 T:G 0.90 [0.85 - 0.95] 1.08 [0.48 - 2.40] 1.44 [0.69 - 3.03] 0.32 0.91 
 
rs1432679 T:C 1.10 [1.07 - 1.14] 1.00 [0.65 - 1.53] 0.91 [0.62 - 1.33] 0.62 0.97 
 
rs1436904 T:G 0.96 [0.92 - 0.99] 1.03 [0.68 - 1.55] 1.06 [0.72 - 1.56] 0.78 0.99 
 
rs1550623 A:G 0.95 [0.91 - 0.99] 0.89 [0.51 - 1.54] 1.06 [0.64 - 1.76] 0.83 0.99 
 
rs16857609 C:T 1.09 [1.05 - 1.13] 1.45 [0.90 - 2.35] 1.30 [0.85 - 1.99] 0.22 0.91 
 
rs17356907 A:G 0.90 [0.87 - 0.93] 0.79 [0.51 - 1.23] 0.97 [0.65 - 1.45] 0.89 0.99 
 
rs17529111 T:C 1.06 [1.03 - 1.11] 1.17 [0.72 - 1.88] 1.10 [0.71 - 1.71] 0.66 0.98 
 
rs17817449 T:G 0.93 [0.90 - 0.97] 0.83 [0.55 - 1.24] 0.95 [0.65 - 1.38] 0.77 0.99 
 
rs2016394 G:A 0.94 [0.91 - 0.97] 1.05 [0.73 - 1.52] 1.12 [0.79 - 1.59] 0.51 0.97 
 
rs204247 A:G 1.06 [1.02 - 1.09] 0.85 [0.57 - 1.27] 0.67 [0.47 - 0.96] 0.030 0.46 
 
rs2046210 G:A 1.07 [1.04 - 1.09] 0.91 [0.65 - 1.26] 0.85 [0.63 - 1.14] 0.28 0.91 
 
rs2236007 G:A 0.92 [0.88 - 0.95] 1.13 [0.69 - 1.84] 1.13 [0.73 - 1.76] 0.58 0.97 
 
rs2363956 A:C 1.02 [0.99 - 1.04] 1.29 [0.89 - 1.86] 1.29 [0.94 - 1.78] 0.11 0.77 
 
rs2380205 C:T 0.97 [0.94 - 0.99] 1.06 [0.77 - 1.45] 1.08 [0.82 - 1.43] 0.57 0.97 
 
rs2588809 C:T 1.09 [1.05 - 1.14] 1.19 [0.66 - 2.14] 1.41 [0.81 - 2.45] 0.21 0.91 
 
rs2736108 C:T 0.94 [0.90 - 0.97] 0.89 [0.57 - 1.40] 1.00 [0.66 - 1.51] 0.99 0.99 
 
rs2823093 G:A 0.92 [0.89 - 0.95] 0.91 [0.64 - 1.30] 0.88 [0.63 - 1.21] 0.43 0.97 
 
rs2943559 A:G 1.14 [1.08 - 1.21] 1.54 [0.69 - 3.43] 1.17 [0.57 - 2.38] 0.66 0.98 
 
rs2981579 G:A 1.31 [1.27 - 1.35] 1.37 [0.91 - 2.07] 1.00 [0.69 - 1.45] 0.99 0.99 
 
rs2981582 G:A 1.31 [1.28 - 1.35] 1.41 [1.02 - 1.94] 1.09 [0.81 - 1.46] 0.57 0.97 
rs3757318 G:A 1.10 [1.04 - 1.16] 1.32 [0.49 - 3.58] 1.29 [0.51 - 3.26] 0.58 0.97 
 
rs3760982 G:A 1.06 [1.03 - 1.10] 1.12 [0.75 - 1.67] 1.05 [0.73 - 1.50] 0.80 0.99 
 
rs3803662 G:A 1.27 [1.24 - 1.30] 0.99 [0.71 - 1.38] 0.85 [0.63 - 1.15] 0.29 0.91 
 
rs3817198 T:C 1.07 [1.05 - 1.10] 1.13 [0.81 - 1.58] 0.98 [0.72 - 1.33] 0.88 0.99 
 
rs3903072 G:T 0.94 [0.91 - 0.97] 1.03 [0.67 - 1.57] 0.99 [0.68 - 1.45] 0.97 0.99 
 
rs4245739 A:C 1.00 [0.96 - 1.03] 1.08 [0.66 - 1.78] 1.13 [0.72 - 1.78] 0.59 0.97 
 
rs4808801 A:G 0.92 [0.89 - 0.95] 0.58 [0.38 - 0.88] 0.67 [0.46 - 0.98] 0.040 0.46 
 
rs4849887 C:T 0.91 [0.86 - 0.96] 1.19 [0.59 - 2.42] 1.21 [0.63 - 2.33] 0.56 0.97 
 
rs4973768 C:T 1.11 [1.08 - 1.13] 1.08 [0.79 - 1.48] 0.91 [0.69 - 1.19] 0.49 0.97 
 
rs527616 G:C 0.96 [0.93 - 0.99] 1.13 [0.74 - 1.71] 1.20 [0.83 - 1.75] 0.33 0.91 
 
rs554219 C:G 1.30 [1.25 - 1.36] 1.36 [0.72 - 2.57] 0.99 [0.55 - 1.77] 0.96 0.99 
 
rs6001930 T:C 1.12 [1.06 - 1.17] 1.01 [0.58 - 1.76] 0.85 [0.51 - 1.42] 0.55 0.97 
 
rs614367 C:T 1.25 [1.21 - 1.29] 1.35 [0.82 - 2.21] 0.97 [0.62 - 1.53] 0.91 0.99 
 
rs616488 A:G 0.95 [0.92 - 0.98] 0.88 [0.56 - 1.38] 0.99 [0.65 - 1.49] 0.94 0.99 
 
rs6472903 T:G 0.92 [0.89 - 0.96] 0.82 [0.48 - 1.39] 0.79 [0.49 - 1.26] 0.32 0.91 
 
rs6504950 G:A 0.93 [0.90 - 0.95] 0.93 [0.66 - 1.31] 1.02 [0.75 - 1.39] 0.91 0.99 
 
rs6678914 G:A 0.99 [0.96 - 1.02] 1.05 [0.69 - 1.60] 1.08 [0.74 - 1.59] 0.69 0.98 
 
rs6762644 A:G 1.07 [1.04 - 1.11] 1.01 [0.67 - 1.53] 0.91 [0.63 - 1.32] 0.61 0.97 
 
rs6828523 C:A 0.87 [0.83 - 0.91] 0.61 [0.32 - 1.18] 0.82 [0.46 - 1.46] 0.50 0.97 
 
rs704010 C:T 1.08 [1.06 - 1.11] 0.81 [0.59 - 1.11] 0.74 [0.55 - 0.98] 0.037 0.46 
 
rs7072776 G:A 1.08 [1.04 - 1.12] 1.46 [0.90 - 2.35] 1.21 [0.79 - 1.86] 0.38 0.91 
 
rs720475 G:A 0.91 [0.88 - 0.95] 0.67 [0.42 - 1.07] 0.76 [0.50 - 1.16] 0.20 0.91 
 
rs75915166 C:A 1.37 [1.28 - 1.45] 2.27 [0.84 - 6.09] 1.63 [0.64 - 4.15] 0.28 0.91 
 
rs7904519 A:G 1.05 [1.02 - 1.09] 1.15 [0.78 - 1.71] 1.08 [0.75 - 1.55] 0.69 0.98 
 
rs8170 G:A 0.99 [0.96 - 1.02] 0.76 [0.52 - 1.11] 0.77 [0.54 - 1.08] 0.13 0.83 
 
rs865686 T:G 0.86 [0.84 - 0.88] 0.89 [0.64 - 1.23] 0.99 [0.74 - 1.32] 0.92 0.99 
 
rs889312 A:C 1.12 [1.09 - 1.15] 0.83 [0.59 - 1.16] 0.68 [0.50 - 0.92] 0.013 0.33 
 
rs941764 A:G 1.06 [1.03 - 1.10] 0.86 [0.57 - 1.29] 0.88 [0.61 - 1.28] 0.50 0.97 
 
rs9693444 C:A 1.07 [1.03 - 1.10] 1.24 [0.81 - 1.88] 1.09 [0.75 - 1.61] 0.64 0.98 
 
rs9790517 C:T 1.04 [1.00 - 1.08] 0.93 [0.57 - 1.51] 0.93 [0.60 - 1.46] 0.77 0.99 
 
a The p-values from likelihood ratio tests have been corrected for multiple testing using the Benjamini-Hochberg method.  
Note: Results in bold indicate pairwise interactions with nominal significance. 
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Figure S1. Relationship between the polygenic risk score (PRS) and positive family history of 
breast cancer.
